Skip to content
IconOVir
  • Contact
  • Contact

Day: November 10, 2022

IconOVir Announces New Preclinical Data Showcasing Best-in-Class Potential of ICVB-1042, its Lead Oncolytic Virus, at SITC 2022

— ICVB-1042 demonstrates selective replication, broad tropism and anti-tumor activity across multiple in vitro and in vivo models — — Proprietary Ad5/Ad34 mutation improves viral entry into target tumor cells, enhancing tropism — — On track to initiate Phase 1 trial in solid tumors in 1H 2023 —  SAN DIEGO, CA., November 10, 2022 – […]

CORPORATE OFFICE

IconOVir Bio
689 Fifth Ave, 12th Floor
New York, NY 10022

info@iconovir.com
Linkedin-in
©2025 IconOVir Bio